{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:21:11Z","timestamp":1791908471237,"version":"4.3.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["82061148017; 82073890; 81673464"],"award-info":[{"award-number":["82061148017; 82073890; 81673464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"major project of tianjin for new drug development","award":["17ZXXYSY00050"],"award-info":[{"award-number":["17ZXXYSY00050"]}]},{"name":"postgraduate innovation fund of \u201813th five-year comprehensive investment\u2019 of tianjin medical university","award":["YJSCX201806"],"award-info":[{"award-number":["YJSCX201806"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The critical role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biology has prompted massive efforts to develop PI3K inhibitors (PI3Kis) for cancer therapy. However, recent results from clinical trials have shown only a modest therapeutic efficacy of single-agent PI3Kis in solid tumors. Targeting autophagy has controversial context-dependent effects in cancer treatment. As a FDA-approved lysosomotropic agent, hydroxychloroquine (HCQ) has been well tested as an autophagy inhibitor in preclinical models. Here, we elucidated the novel mechanism of HCQ alone or in combination with PI3Ki BKM120 in the treatment of cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The antitumor effects of HCQ and BKM120 on three different types of tumor cells were assessed by in vitro PrestoBlue assay, colony formation assay and in vivo zebrafish and nude mouse xenograft models. The involved molecular mechanisms were investigated by MDC staining, LC3 puncta formation assay, immunofluorescent assay, flow cytometric analysis of apoptosis and ROS, qRT-PCR, Western blot, comet assay, homologous recombination (HR) assay and immunohistochemical staining.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HCQ significantly sensitized cancer cells to BKM120 in vitro and in vivo. Interestingly, the sensitization mediated by HCQ could not be phenocopied by treatment with other autophagy inhibitors (Spautin-1, 3-MA and bafilomycin A1) or knockdown of the essential autophagy genes Atg5\/Atg7, suggesting that the sensitizing effect might be mediated independent of autophagy status. Mechanistically, HCQ induced ROS production and activated the transcription factor NRF2. In contrast, BKM120 prevented the elimination of ROS by inactivation of NRF2, leading to accumulation of DNA damage. In addition, HCQ activated ATM to enhance HR repair, a high-fidelity repair for DNA double-strand breaks (DSBs) in cells, while BKM120 inhibited HR repair by blocking the phosphorylation of ATM and the expression of BRCA1\/2 and Rad51.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study revealed that HCQ and BKM120 synergistically increased DSBs in tumor cells and therefore augmented apoptosis, resulting in enhanced antitumor efficacy. Our findings provide a new insight into how HCQ exhibits antitumor efficacy and synergizes with PI3Ki BKM120, and warn that one should consider the \u201coff target\u201d effects of HCQ when used as autophagy inhibitor in the clinical treatment of cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-021-02176-2","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T08:02:53Z","timestamp":1638172973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy"],"prefix":"10.1186","volume":"40","author":[{"given":"Xin","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois X.","family":"Claret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Elkabets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexin","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"2176_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cell.2015.12.042","volume":"164","author":"H Hu","year":"2016","unstructured":"Hu H, Juvekar A, Lyssiotis CA, Lien EC, Albeck JG, Oh D, et al. Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton. Cell. 2016;164:433\u201346.","journal-title":"Cell."},{"key":"2176_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","volume":"560","author":"BD Hopkins","year":"2018","unstructured":"Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560:499\u2013503.","journal-title":"Nature."},{"key":"2176_CR3","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","volume":"21","author":"BW Miller","year":"2015","unstructured":"Miller BW, Przepiorka D, de Claro RA, Lee K, Nie L, Simpson N, et al. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma. Clin Cancer Res. 2015;21:1525\u20139.","journal-title":"Clin Cancer Res"},{"key":"2176_CR4","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/annonc\/mdx289","volume":"28","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, et al. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169\u201378.","journal-title":"Ann Oncol"},{"key":"2176_CR5","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","volume":"35","author":"M Dreyling","year":"2017","unstructured":"Dreyling M, Santoro A, Mollica L, Leppa S, Follows GA, Lenz G, et al. Phosphatidylinositol 3-kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35:3898\u2013905.","journal-title":"J Clin Oncol"},{"key":"2176_CR6","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M, Nagy Z, Illes A, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood. 2018;132:2446\u201355.","journal-title":"Blood."},{"key":"2176_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","volume":"31","author":"HS Rugo","year":"2020","unstructured":"Rugo HS, Andre F, Yamashita T, Cerda H, Toledano I, Stemmer SM, et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann Oncol. 2020;31:1001\u201310.","journal-title":"Ann Oncol"},{"key":"2176_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","volume":"18","author":"J Yang","year":"2019","unstructured":"Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer. 2019;18:26.","journal-title":"Mol Cancer"},{"key":"2176_CR9","doi-asserted-by":"crossref","unstructured":"Vanhaesebroeck B, Perry MWD, Brown JR, Andre F, Okkenhaug K. PI3K inhibitors are finally coming of age. Nat Rev Drug Discov. 2021;20:741\u201369.","DOI":"10.1038\/s41573-021-00209-1"},{"key":"2176_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","volume":"15","author":"F Janku","year":"2018","unstructured":"Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018;15:273\u201391.","journal-title":"Nat Rev Clin Oncol"},{"key":"2176_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s40425-018-0457-0","volume":"6","author":"LA-O Carnevalli","year":"2018","unstructured":"Carnevalli LA-O, Sinclair C, Taylor MA, Gutierrez PM, Langdon S, Coenen-Stass AML, et al. PI3K\u03b1\/\u03b4 inhibition promotes anti-tumor immunity through direct enhancement of effector CD8(+) T-cell activity. J Immunother Cancer. 2018;6:158.","journal-title":"J Immunother Cancer"},{"issue":"Suppl 10","key":"2176_CR12","doi-asserted-by":"publisher","first-page":"x27","DOI":"10.1093\/annonc\/mdz280","volume":"30","author":"M Brand\u00e3o","year":"2019","unstructured":"Brand\u00e3o M, Caparica R, Eiger D, de Azambuja E. Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. Ann Oncol. 2019;30(Suppl 10):x27\u201342.","journal-title":"Ann Oncol"},{"key":"2176_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15:7\u201324.","journal-title":"Nat Rev Cancer"},{"key":"2176_CR14","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-16-2142","volume":"23","author":"J Sai","year":"2017","unstructured":"Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, et al. PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and anti-PD1 responses. Clin Cancer Res. 2017;23:3371\u201384.","journal-title":"Clin Cancer Res"},{"key":"2176_CR15","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/onc.2017.339","volume":"37","author":"MR Yun","year":"2018","unstructured":"Yun MR, Choi HM, Kang HN, Lee Y, Joo HS, Kim DH, et al. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. Oncogene. 2018;37:377\u201388.","journal-title":"Oncogene."},{"key":"2176_CR16","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","volume":"2","author":"YH Ibrahim","year":"2012","unstructured":"Ibrahim YH, Garc\u00eda-Garc\u00eda C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2:1036\u201347.","journal-title":"Cancer Discov"},{"key":"2176_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ccell.2014.11.008","volume":"27","author":"S Schwartz","year":"2015","unstructured":"Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, et al. Feedback suppression of PI3K\u03b1 signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3K\u03b2. Cancer Cell. 2015;27:109\u201322.","journal-title":"Cancer Cell"},{"key":"2176_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.apsb.2016.07.006","volume":"7","author":"W Zhao","year":"2017","unstructured":"Zhao W, Qiu Y, Kong D. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharm Sin B. 2017;7:27\u201337.","journal-title":"Acta Pharm Sin B"},{"key":"2176_CR19","unstructured":"National Institutes of Health (U.S.), National Library of Medicine (U.S.), United States. Food and Drug Administration. ClinicalTrials.gov."},{"key":"2176_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0163-7258(93)90056-J","volume":"57","author":"AF Slater","year":"1993","unstructured":"Slater AF. Chloroquine: mechanism of drug action and resistance in plasmodium falciparum. Pharmacol Ther. 1993;57:203\u201335.","journal-title":"Pharmacol Ther"},{"key":"2176_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-019-1795-x","volume":"576","author":"J Kim","year":"2019","unstructured":"Kim J, Tan YZ, Wicht KJ, Erramilli SK, Dhingra SK, Okombo J, et al. Structure and drug resistance of the plasmodium falciparum transporter PfCRT. Nature. 2019;576:315\u201320.","journal-title":"Nature."},{"key":"2176_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","volume":"23","author":"KD Rainsford","year":"2015","unstructured":"Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231\u201369.","journal-title":"Inflammopharmacology."},{"key":"2176_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ebiom.2017.09.034","volume":"24","author":"C Li","year":"2017","unstructured":"Li C, Zhu X, Ji X, Quanquin N, Deng YQ, Tian M, et al. Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice. EBioMedicine. 2017;24:189\u201394.","journal-title":"EBioMedicine."},{"key":"2176_CR24","doi-asserted-by":"publisher","first-page":"6027","DOI":"10.1096\/fj.202000919","volume":"34","author":"EA Meyerowitz","year":"2020","unstructured":"Meyerowitz EA, Vannier AGL, Friesen MGN, Schoenfeld S, Gelfand JA, Callahan MV, et al. Rethinking the role of hydroxychloroquine in the treatment of COVID-19. FASEB J. 2020;34:6027\u201337.","journal-title":"FASEB J"},{"key":"2176_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107672","volume":"216","author":"ZN Lei","year":"2020","unstructured":"Lei ZN, Wu ZX, Dong S, Yang DH, Zhang L, Ke Z, et al. Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. Pharmacol Ther. 2020;216:107672.","journal-title":"Pharmacol Ther"},{"key":"2176_CR26","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1080\/15548627.2017.1377377","volume":"13","author":"S Piao","year":"2017","unstructured":"Piao S, Ojha R, Rebecca VW, Samanta A, Ma XH, McAfee Q, et al. ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells. Autophagy. 2017;13:2056\u201371.","journal-title":"Autophagy."},{"key":"2176_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1158\/2159-8290.CD-18-0706","volume":"9","author":"VW Rebecca","year":"2019","unstructured":"Rebecca VW, Nicastri MC, Fennelly C, Chude CI, Barber-Rotenberg JS, Ronghe A, et al. PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov. 2019;9:220\u20139.","journal-title":"Cancer Discov"},{"key":"2176_CR28","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1158\/1078-0432.CCR-16-2426","volume":"23","author":"F Zhou","year":"2017","unstructured":"Zhou F, Pan Y, Wei Y, Zhang R, Bai G, Shen Q, et al. Jab1\/Csn5-Thioredoxin signaling in relapsed acute monocytic leukemia under oxidative stress. Clin Cancer Res. 2017;23:4450\u201361.","journal-title":"Clin Cancer Res"},{"key":"2176_CR29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/hep.28372","volume":"63","author":"H Guo","year":"2016","unstructured":"Guo H, Jing L, Cheng Y, Atsaves V, Lv Y, Wu T, et al. Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1\/Csn5 in hepatocarcinogenesis. Hepatology. 2016;63:898\u2013913.","journal-title":"Hepatology."},{"key":"2176_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-019-1112-1","volume":"19","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li Y, Wang Q, Chen Z, Li X, Wu Z, et al. The PI3K subunits, P110alpha and P110beta are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol Cancer. 2020;19:10.","journal-title":"Mol Cancer"},{"key":"2176_CR31","doi-asserted-by":"publisher","first-page":"19897","DOI":"10.18632\/oncotarget.7658","volume":"7","author":"Y Wang","year":"2016","unstructured":"Wang Y, Liu J, Qiu Y, Jin M, Chen X, Fan G, et al. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells. Oncotarget. 2016;7:19897\u2013909.","journal-title":"Oncotarget."},{"key":"2176_CR32","doi-asserted-by":"publisher","first-page":"27071","DOI":"10.1038\/srep27071","volume":"6","author":"R Wang","year":"2016","unstructured":"Wang R, Zhang Q, Peng X, Zhou C, Zhong Y, Chen X, et al. Stellettin B induces G1 arrest, apoptosis and autophagy in human non-small cell lung cancer A549 cells via blocking PI3K\/Akt\/mTOR pathway. Sci Rep. 2016;6:27071.","journal-title":"Sci Rep"},{"key":"2176_CR33","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1096\/fj.201800183R","volume":"32","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Liu J, Wang Y, Tan X, Zhao W, Xing X, et al. Phosphatidylinositol 3-kinase beta and delta isoforms play key roles in metastasis of prostate cancer DU145 cells. FASEB J. 2018;32:5967\u201375.","journal-title":"FASEB J"},{"key":"2176_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2018.10.007","volume":"440-441","author":"N Ji","year":"2019","unstructured":"Ji N, Yang Y, Cai CY, Lei ZN, Wang JQ, Gupta P, et al. Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Lett. 2019;440-441:82\u201393.","journal-title":"Cancer Lett"},{"key":"2176_CR35","doi-asserted-by":"crossref","unstructured":"Zhang Z, Wang Y, Ma Q, Zhang S, Liu H, Zhao B, et al. Biomimetic carrier-free nanoparticle delivers digoxin and doxorubicin to exhibit synergetic antitumor activity in vitro and in vivo. Chem Eng J. 2021;406:126801.","DOI":"10.1016\/j.cej.2020.126801"},{"key":"2176_CR36","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fphar.2020.00186","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang Y, Ma Q, Zhang S, Liu H, Zhao B, Du B, et al. Digoxin enhances the anticancer effect on non-small cell lung cancer while reducing the cardiotoxicity of Adriamycin. Front Pharmacol. 2020;11:186.","journal-title":"Front Pharmacol"},{"key":"2176_CR37","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1038\/onc.2010.345","volume":"29","author":"L Tian","year":"2010","unstructured":"Tian L, Peng G, Parant JM, Leventaki V, Drakos E, Zhang Q, et al. Essential roles of Jab1 in cell survival, spontaneous DNA damage and DNA repair. Oncogene. 2010;29:6125\u201337.","journal-title":"Oncogene."},{"key":"2176_CR38","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41419-021-03805-6","volume":"12","author":"S Zhang","year":"2021","unstructured":"Zhang S, Peng X, Li X, Liu H, Zhao B, Elkabets M, et al. BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair. Cell Death Dis. 2021;12:546.","journal-title":"Cell Death Dis"},{"key":"2176_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12943-020-01256-9","volume":"19","author":"W Wang","year":"2020","unstructured":"Wang W, Zhao M, Cui L, Ren Y, Zhang J, Chen J, et al. Characterization of a novel HDAC\/RXR\/HtrA1 signaling axis as a novel target to overcome cisplatin resistance in human non-small cell lung cancer. Mol Cancer. 2020;19:134.","journal-title":"Mol Cancer"},{"key":"2176_CR40","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.ejca.2010.01.005","volume":"46","author":"D Kong","year":"2010","unstructured":"Kong D, Dan S, Yamazaki K, Yamori T. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur J Cancer. 2010;46:1111\u201321.","journal-title":"Eur J Cancer"},{"key":"2176_CR41","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1016\/j.bmc.2012.01.017","volume":"20","author":"D Kong","year":"2012","unstructured":"Kong D, Yamori T. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg Med Chem. 2012;20:1947\u201351.","journal-title":"Bioorg Med Chem"},{"key":"2176_CR42","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s10637-014-0152-z","volume":"32","author":"D Kong","year":"2014","unstructured":"Kong D, Yamori T, Yamazaki K, Dan S. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA. Invest New Drugs. 2014;32:1134\u201343.","journal-title":"Invest New Drugs"},{"key":"2176_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1172\/JCI73939","volume":"125","author":"YC Kim","year":"2015","unstructured":"Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation. J Clin Invest. 2015;125:25\u201332.","journal-title":"J Clin Invest"},{"key":"2176_CR44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.4161\/auto.4451","volume":"3","author":"S Kimura","year":"2007","unstructured":"Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy. 2007;3:452\u201360.","journal-title":"Autophagy."},{"key":"2176_CR45","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.cell.2011.08.037","volume":"147","author":"J Liu","year":"2011","unstructured":"Liu J, Xia H, Kim M, Xu L, Li Y, Zhang L, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell. 2011;147:223\u201334.","journal-title":"Cell."},{"key":"2176_CR46","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1158\/2159-8290.CD-13-0397","volume":"3","author":"AM Strohecker","year":"2013","unstructured":"Strohecker AM, Guo JY, Karsli-Uzunbas G, Price SM, Chen GJ, Mathew R, et al. Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov. 2013;3:1272\u201385.","journal-title":"Cancer Discov"},{"key":"2176_CR47","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.molcel.2014.07.019","volume":"55","author":"R Mathew","year":"2014","unstructured":"Mathew R, Khor S, Hackett SR, Rabinowitz JD, Perlman DH, White E. Functional role of autophagy-mediated proteome remodeling in cell survival signaling and innate immunity. Mol Cell. 2014;55:916\u201330.","journal-title":"Mol Cell"},{"key":"2176_CR48","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1247\/csf.23.33","volume":"23","author":"A Yamamoto","year":"1998","unstructured":"Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct. 1998;23:33\u201342.","journal-title":"Cell Struct Funct"},{"key":"2176_CR49","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4161\/auto.22397","volume":"9","author":"DY Ouyang","year":"2013","unstructured":"Ouyang DY, Xu LH, He XH, Zhang YT, Zeng LH, Cai JY, et al. Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy. 2013;9:20\u201332.","journal-title":"Autophagy."},{"key":"2176_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","volume":"34","author":"M Rojo de la Vega","year":"2018","unstructured":"Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34:21\u201343.","journal-title":"Cancer Cell"},{"key":"2176_CR51","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/cdd.2009.154","volume":"17","author":"KRS-W Choi","year":"2010","unstructured":"Choi KRS-W, Song S, Choi H, Kang SW, Choi C. Caspase-dependent generation of reactive oxygen species in human astrocytoma cells contributes to resistance to TRAIL-mediated apoptosis. Cell Death Differ. 2010;17:833\u201345.","journal-title":"Cell Death Differ"},{"key":"2176_CR52","doi-asserted-by":"publisher","first-page":"5080843","DOI":"10.1155\/2019\/5080843","volume":"2019","author":"LJ Su","year":"2019","unstructured":"Su LJ, Zhang JH, Gomez H, Murugan R, Hong X, Xu D, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev. 2019;2019:5080843.","journal-title":"Oxid Med Cell Longev"},{"key":"2176_CR53","first-page":"862","volume":"59","author":"A Ravid","year":"1999","unstructured":"Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, et al. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res. 1999;59:862\u20137.","journal-title":"Cancer Res"},{"key":"2176_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081162","volume":"8","author":"R Marullo","year":"2013","unstructured":"Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS, et al. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One. 2013;8:e81162.","journal-title":"PLoS One"},{"key":"2176_CR55","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/cr.2016.95","volume":"26","author":"M Gao","year":"2016","unstructured":"Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X. Ferroptosis is an autophagic cell death process. Cell Res. 2016;26:1021\u201332.","journal-title":"Cell Res"},{"key":"2176_CR56","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s12276-020-0384-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, et al. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52:192\u2013203.","journal-title":"Exp Mol Med"},{"key":"2176_CR57","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012716","volume":"5","author":"A Mar\u00e9chal","year":"2013","unstructured":"Mar\u00e9chal A, Zou L. DNA damage sensing by the ATM and ATR kinases. Cold Spring Harb Perspect Biol. 2013;5:a012716.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2176_CR58","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/ard.57.10.582","volume":"57","author":"JA Avi\u00f1a-Zubieta","year":"1988","unstructured":"Avi\u00f1a-Zubieta JA, Galindo-Rodriguez G, Newman S, Suarez Almazor ME, Russell AS. Long-term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis. 1988;57:582\u20137.","journal-title":"Ann Rheum Dis"},{"key":"2176_CR59","doi-asserted-by":"publisher","DOI":"10.4161\/mco.29911","volume":"1","author":"G Manic","year":"2014","unstructured":"Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 2014;1:e29911.","journal-title":"Mol Cell Oncol"},{"key":"2176_CR60","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012476","volume":"12","author":"EL Nirk","year":"2020","unstructured":"Nirk EL, Reggiori F, Mauthe M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond. EMBO Mol Med. 2020;12:e12476.","journal-title":"EMBO Mol Med"},{"key":"2176_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100146","volume":"1","author":"N Rother","year":"2020","unstructured":"Rother N, Yanginlar C, Lindeboom RGH, Bekkering S, van Leent MMT, Buijsers B, et al. Hydroxychloroquine inhibits the trained innate immune response to interferons. Cell Rep Med. 2020;1:100146.","journal-title":"Cell Rep Med"},{"key":"2176_CR62","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1158\/1078-0432.CCR-12-3114","volume":"19","author":"F Lamoureux","year":"2013","unstructured":"Lamoureux F, Thomas C, Crafter C, Kumano M, Zhang F, Davies BR, et al. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res. 2013;19:833\u201344.","journal-title":"Clin Cancer Res"},{"key":"2176_CR63","doi-asserted-by":"publisher","first-page":"15916","DOI":"10.1038\/ncomms15916","volume":"8","author":"S Vijayaraghavan","year":"2017","unstructured":"Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, et al. CDK4\/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017;8:15916.","journal-title":"Nat Commun"},{"key":"2176_CR64","doi-asserted-by":"publisher","first-page":"200","DOI":"10.4161\/auto.8.2.18554","volume":"8","author":"P Maycotte","year":"2012","unstructured":"Maycotte P, Aryal S, Cummings CT, Thorburn J, Morgan MJ, Thorburn A. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy. 2012;8:200\u201312.","journal-title":"Autophagy."},{"key":"2176_CR65","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ccr.2014.06.025","volume":"26","author":"H Maes","year":"2014","unstructured":"Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, et al. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell. 2014;26:190\u2013206.","journal-title":"Cancer Cell"},{"key":"2176_CR66","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1073\/pnas.1515617113","volume":"113","author":"CH Eng","year":"2016","unstructured":"Eng CH, Wang Z, Tkach D, Toral-Barza L, Ugwonali S, Liu S, et al. Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy. Proc Natl Acad Sci U S A. 2016;113:182\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2176_CR67","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/cdd.2014.150","volume":"22","author":"G Filomeni","year":"2015","unstructured":"Filomeni G, De Zio D, Cecconi F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 2015;22:377\u201388.","journal-title":"Cell Death Differ"},{"key":"2176_CR68","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/ncb2021","volume":"12","author":"M Komatsu","year":"2010","unstructured":"Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, et al. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol. 2010;12:213\u201323.","journal-title":"Nat Cell Biol"},{"key":"2176_CR69","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.redox.2012.10.001","volume":"1","author":"E Kansanen","year":"2013","unstructured":"Kansanen E, Kuosmanen SM, Leinonen H, AL. L. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013;1:45\u20139.","journal-title":"Redox Biol"},{"key":"2176_CR70","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1158\/2159-8290.CD-16-0127","volume":"7","author":"Y Jeong","year":"2017","unstructured":"Jeong Y, Hoang NT, Lovejoy A, Stehr H, Newman AM, Gentles AJ, et al. Role of KEAP1\/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance. Cancer Discov. 2017;7:86\u2013101.","journal-title":"Cancer Discov"},{"key":"2176_CR71","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12551-016-0244-4","volume":"9","author":"P Deshmukh","year":"2017","unstructured":"Deshmukh P, Unni S, Krishnappa G, Padmanabhan B. The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017;9:41\u201356.","journal-title":"Biophys Rev"},{"key":"2176_CR72","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.celrep.2019.06.047","volume":"28","author":"T Suzuki","year":"2019","unstructured":"Suzuki T, Muramatsu A, Saito R, Iso T, Shibata T, Kuwata K, et al. Molecular mechanism of cellular oxidative stress sensing by Keap1. Cell Rep. 2019;28:746\u201358.","journal-title":"Cell Rep"},{"key":"2176_CR73","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0014-5793(03)00517-9","volume":"546","author":"K Nakaso","year":"2003","unstructured":"Nakaso K, Yano H, Fukuhara Y, Takeshima T, Wada-Isoe K, Nakashima KJFl. PI3K is a key molecule in the Nrf2-mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells. FEBS Lett. 2003;546:181\u20134.","journal-title":"FEBS Lett"},{"key":"2176_CR74","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","volume":"475","author":"GM DeNicola","year":"2011","unstructured":"DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475:106\u20139.","journal-title":"Nature."},{"key":"2176_CR75","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.1073\/pnas.1324136111","volume":"111","author":"C Gorrini","year":"2014","unstructured":"Gorrini C, Gang BP, Bassi C, Wakeham A, Baniasadi SP, Hao Z, et al. Estrogen controls the survival of BRCA1-deficient cells via a PI3K\u2013NRF2-regulated pathway. Proc Natl Acad Sci U S A. 2014;111:4472\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2176_CR76","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature01368","volume":"421","author":"CJ Bakkenist","year":"2003","unstructured":"Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499\u2013506.","journal-title":"Nature."},{"key":"2176_CR77","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0014-5793(95)00144-X","volume":"361","author":"WA Krajewski","year":"1995","unstructured":"Krajewski WA. Alterations in the internucleosomal DNA helical twist in chromatin of human erythroleukemia cells in vivo influences the chromatin higher-order folding. FEBS Lett. 1995;361:149\u201352.","journal-title":"FEBS Lett"},{"key":"2176_CR78","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ijrobp.2009.04.088","volume":"75","author":"L Xue","year":"2009","unstructured":"Xue L, Yu D, Furusawa Y, Cao J, Okayasu R, Fan S. ATM-dependent hyper-radiosensitivity in mammalian cells irradiated by heavy ions. Int J Radiat Oncol Biol Phys. 2009;75:235\u201343.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2176_CR79","doi-asserted-by":"crossref","unstructured":"Qian M, Liu Z, Peng L, Tang X, Meng F, Ao Y, et al. Boosting ATM activity alleviates aging and extends lifespan in a mouse model of progeria. Elife. 2018;7:e34836.","DOI":"10.7554\/eLife.34836"},{"key":"2176_CR80","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/2159-8290.CD-11-0336","volume":"2","author":"A Juvekar","year":"2012","unstructured":"Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balma\u00f1\u00e0 J, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2:1048\u201363.","journal-title":"Cancer Discov"},{"key":"2176_CR81","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/cancers12030532","volume":"12","author":"F Gallyas Jr","year":"2020","unstructured":"Gallyas F Jr, Sumegi B, Szabo C. Role of Akt activation in PARP inhibitor resistance in cancer. Cancers (Basel). 2020;12:523.","journal-title":"Cancers (Basel)"},{"key":"2176_CR82","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-15-1772","volume":"22","author":"W Mo","year":"2016","unstructured":"Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, et al. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple-negative breast cancer. Clin Cancer Res. 2016;22:1699\u2013712.","journal-title":"Clin Cancer Res"},{"key":"2176_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E. PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601.","journal-title":"Front Cell Dev Biol"},{"key":"2176_CR84","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/S1470-2045(18)30905-7","volume":"20","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, et al. Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20:570\u201380.","journal-title":"Lancet Oncol"},{"key":"2176_CR85","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-019-08530-5","volume":"10","author":"C Bian","year":"2019","unstructured":"Bian C, Zhang C, Luo T, Vyas A, Chen SH, Liu C, et al. NADP(+) is an endogenous PARP inhibitor in DNA damage response and tumor suppression. Nat Commun. 2019;10:693.","journal-title":"Nat Commun"},{"key":"2176_CR86","first-page":"473","volume":"7","author":"Y Yin","year":"2017","unstructured":"Yin Y, Shen Q, Zhang P, Tao R, Chang W, Li R, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017;7:473\u201383.","journal-title":"Am J Cancer Res"},{"key":"2176_CR87","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1073\/pnas.0914242107","volume":"107","author":"A Kumar","year":"2010","unstructured":"Kumar A, Fernandez-Capetillo O, Carrera AC. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc Natl Acad Sci U S A. 2010;107:7491\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2176_CR88","doi-asserted-by":"publisher","first-page":"8882","DOI":"10.1073\/pnas.0602911103","volume":"103","author":"CE Irarrazabal","year":"2006","unstructured":"Irarrazabal CE, Burg MB, Ward SG, Ferraris JD. Phosphatidylinositol 3-kinase mediates activation of ATM by high NaCl and by ionizing radiation: role in osmoprotective transcriptional regulation. Proc Natl Acad Sci U S A. 2006;103:8882\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2176_CR89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.chembiol.2014.11.013","volume":"22","author":"M Srivastava","year":"2015","unstructured":"Srivastava M, Raghavan SC. DNA double-strand break repair inhibitors as cancer therapeutics. Chem Biol. 2015;22:17\u201329.","journal-title":"Chem Biol"}],"updated-by":[{"DOI":"10.1186\/s13046-021-02218-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T00:00:00Z","timestamp":1639958400000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02176-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-021-02176-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02176-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T17:05:09Z","timestamp":1675962309000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-021-02176-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2176"],"URL":"https:\/\/doi.org\/10.1186\/s13046-021-02176-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-691658\/v1","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"6 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-021-02218-9","URL":"https:\/\/doi.org\/10.1186\/s13046-021-02218-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments were conducted according to the guidelines for the care and use of laboratory animals approved by the local Laboratory Animal Ethics Committee of the State Key Laboratory of Toxicology and Medical Countermeasures of Beijing Institute of Pharmacology and Toxicology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"374"}}